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ORIGINAL ARTICLEAntimicrobial Peptide Human Neutrophil Peptide 1 as a
Potential Link Between Chronic Inflammation and
Ductal Adenocarcinoma of the Pancreas
Thomas Pausch, MD,* Sarah Adolph,* Klaus Felix, PhD,* Andrea S. Bauer, PhD,†
Frank Bergmann, MD,‡ Jens Werner, MD,*§ and Werner Hartwig, MD*||Objectives: Defensins are antimicrobial peptides playing a role in in-
nate immunity, in epithelial cell regeneration, and in carcinogenesis of
inflammation-triggered malignancies. We analyzed this role in pancreatic
ductal adenocarcinoma (PDAC) in the context of its association with chronic
pancreatitis (CP).
Methods: Human tissue of healthy pancreas, CP, and PDAC was screened
for defensins by immunohistochemistry. Defensin α 1 (human neutrophil
peptide 1 [HNP-1]) expression was validated using mass spectrometry and
microarray analysis. Human neutrophil peptide 1 expression and influences
of proinflammatory cytokines (tumor necrosis factor α, interleukin 1β, and
interferon γ) were studied in human pancreatic cancer cells (Colo 357,
T3M4, PANC-1) and normal human pancreatic duct epithelial cells (HPDE).
Results: Accumulation of HNP-1 in malignant pancreatic ductal epithelia
was seen. Spectrometry showed increased expression of HNP-1 in CP and
even more in PDAC. At RNA level, no significant regulation was found. In
cancer cells, HNP-1 expression was significantly higher than in HPDE.
Proinflammatory cytokines significantly led to increased HNP-1 levels in
culture supernatants and decreased levels in lysates of cancer cells. In
HPDE cytokines significantly decreased HNP-1 levels.
Conclusions: Inflammatory regulation of HNP-1 in PDAC tissue and cells
indicates that HNP-1 may be a link between chronic inflammation and ma-
lignant transformation in the pancreas.
Key Words: antimicrobial peptides, pancreas, adenocarcinoma,
chronic pancreatitis
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P ancreatic ductal adenocarcinoma (PDAC) is one of the mostdeadly tumors with less than 5% survival after 5 years; it is
among the 5 leading causes of tumor death in the United
States.1 Early surgery remains the only potentially curative treat-
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Copyright © 2018 Wolters Kluwer still largely defies any medical therapy.2 Recent progress has been
made in the understanding of carcinogenesis with advances in
molecular biology, but until now, only a little therapeutic progress
has resulted. Epigenetic changes and familial syndromes have
been associated with PDAC,3,4 which still does not explain the
disease epidemiologically.5 The most consistent epidemiological
risk factor for developing PDAC is chronic pancreatitis (CP).6,7
There is an increasingly high risk of pancreatic cancer in individ-
uals with hereditary pancreatitis over the age of 50 years8 with a
cumulative lifetime risk of 40% at the age of 70 years.9 Neverthe-
less, the genetic changes that cause CP have not been found in
sporadic pancreatic cancer.10 Consequently, it has been postulated
that genetic susceptibility in interaction with environmental fac-
tors and an altered immune response causes recurrent and largely
asymptomatic pancreatic injury, which progresses to chronic in-
flammation, fibrosis, and over time to malignant transformation
of the pancreas.10,11
The concept of cancer diseases as “wounds that do not heal”
goes back to Virchow's observation of leukocytes in malignant
tissue in 1863.12 The difference between wound healing and can-
cer is the lack of self-limitation of the proliferation of the malig-
nant cells. During carcinogenesis, the mechanisms that would
physiologically repair or eliminate the dysplastic cells fail. Tumor
cells in cooperation with their stroma abuse the immune system to
recruit or deceive various inflammatory cells and create an enriched
cytokine milieu, which protects the tumor cells and supports their
growth.13 So-called defensins are important immune factors. These
small cationic antimicrobial proteins link the innate to the adaptive
immune system. Defensins are expressed by various epithelia and
leucocytes (some of them are named human neutrophil peptides
[HNPs]), to protect the body's surfaces against pathogens.14,15
During the recurrent asymptomatic inflammatory processes that
lead to carcinogenesis in the pancreas, these immune factors
may possibly be switched-off or abused by cancer cells. Pancre-
atic ductal adenocarcinoma is known for its strong desmoplastic
reaction, which involves complex intercellular interactions in the
tumor microenvironment that promote malignant transformation,
invasion, metastasis, and resistance to chemotherapy.16,17 Further-
more, defensins in general are well known for participating in multi-
ple regulations of acute and chronic inflammatory, regenerative, and
proliferative processes.15,18
Defensins have multiple and partly contrary effects on cancer
cells. Some defensins disturb the development of malignant
cells19,20 or destroy them directly15,21 or via immunological
modulation.22 In contrast, other defensins support the proliferation
or migration of malignant cells.20,23 The differential expression of
defensins has been described in several gastrointestinal tumors.24,25
In the pathogenesis of CP and PDAC, defensins seem to play a cer-
tain role. Although their pathogenetic role is not yet fully clarified,
defensins have been detected in pancreatic tissue, in fetal and
adult acinar cells, and also in pancreatic juice.26,27 Likewise, se-
vere acute pancreatitis has been associated with polymorphismswww.pancreasjournal.com 561
Health, Inc. All rights reserved.
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pancreatic metaplasia.29
We assume that disturbances of the regulative function of
defensins, possibly triggered by chronic inflammation, could pro-
mote malignant transformation and tumor growth within the pan-
creas. During the inflammatory process, defensins may either be
switched off or the cancer may abuse their functions. The aim of
the present study was to analyze the role of defensins in the carci-
nogenesis of PDAC and its association with CP.MATERIALS AND METHODS
Patients and Specimens
Tissue samples were obtained from patients in whom pancre-
atic resection had been performed for PDAC andCP at the Depart-
ment of General Surgery, University Hospital in Heidelberg,
Germany between 2001 and 2010. Patients had given informed
consent to the collection of tissue. Normal pancreas specimens
were collected from patients who had undergone resection of pan-
creatic tissue with nonmalignant and noninflammatory diagnoses
(eg. benign cystic lesions). This collection was performed in ac-
cordance to the Helsinki Declaration and approved by the Ethics
Committee of the University of Heidelberg (Votum 301/2001).
A pathologist ascertained that the diagnosis corresponded to the
World Health Organization classification. All specimens for use
in immunhistochemistry were fixed in paraformaldehyde solution
for 12 to 24 hours immediately after surgery and were paraffin
embedded for histological analysis. Specimens for use in expres-
sion analysis and genome analysis were immediately snap frozen
in liquid nitrogen and stored at −80°C until use.
Immunhistochemistry in Pancreatic Tissue
Human tissue samples of the normal pancreas, CP, and
PDAC were screened for defensins using immunohistochemistry
(n = 20 per group). Paraffin-embedded sections (4-μm) of speci-
mens of normal pancreas, CP, and PDAC were deparaffinized
(Roticlear, Carl Roth, Karlsruhe, Germany), rehydrated in pro-
gressively decreasing concentrations of ethanol, and put on slides.
For antigen retrieval, the slides were pretreated in citrate buffer
(pH 6.0) for 2  7 minutes in a microwave oven. They were
washed with water before they were incubated in 3% H2O2/
methanol at room temperature for 10 minutes to quench endoge-
nous peroxidase activity. Slides were rinsed in Tris-buffered saline
(TBS, pH 7.4; Sigma-Aldrich, St Louis, Mo) with 1% bovine se-
rum albumin (BSA; Sigma-Aldrich) for 2  10 minutes to block
nonspecific activity. Incubation of the slides with the following
corresponding primary antibodies was performed overnight in a
4°C humidity chamber (data are presented in Table 1): anti-
human defensin β 1, β 2, β 3, α 1, α 3, α 5, and α 6. For the stain-
ing of the infiltrating inflammatory cells, anti-humanCD15 primary
antibody was used according to the manufacturer's instructions
(Table 1). Again, the slides were washed with TBS/BSA and
0.05% Tween (Sigma-Aldrich) for 3  10 minutes and with
TBS/BSA for 2  10 minutes. Appropriate horseradish peroxidase-
linked goat anti-rabbit (K4003, DAKO, Glostrup, Denmark) or
goat anti-mouse (K4001, DAKO) secondary antibodies were added
for incubation in a humidity chamber at room temperature for
90 minutes, followed by reaction with diaminobenzidine and
counterstaining with Mayer's hematoxylin (S3309, DAKO)
before the mounting of the specimens. Corresponding positive
control sections of human tissue from skeletal muscle or tonsil
were incubated with the primary antibodies to ensure adequate
antibody functioning. Negative controls were incubated in the562 www.pancreasjournal.com
Copyright © 2018 Wolters Kluwer Habsence of the primary antibodies. A pancreas-specialized
pathologist (F.B.) evaluated the immunohistological staining.
Expression Analysis of HNP-1 in Pancreatic Tissue
The protein lysates from human pancreatic tissue of normal
pancreas, CP, and PDAC (n = 10 per group), which were selected
by evaluation of representative HE stainings from each tissue
sample by a pathologist (F.B.), were profiled by applying mass
spectrometry (surface-enhanced laser desorbtion/ionization time-of-
flight mass spectrometry [SELDI-TOF-MS]) and by the use of a
ProteinChip Reader (PBS II; Ciphergen Biosystems, Fremont,
Calif ). Pancreatic tissue was broken down in radioimmunoprecipi-
tation assay buffer (RIPAbuffer, Sigma-Aldrich) to lysate by repeated
aspiration through a cannula before ultrasound-homogenization.
BCA Protein Assay Kit (Thermo Scientific, Waltham, Mass) was
used according to the manufacturer's protocol to equalize the total
amount of proteins between the probes. All probes were immedi-
ately frozen at −80°C and stored until analysis.
Probes were put on PS20 ProteinChip preactivated surface ar-
rays (Ciphergen Biosystems) for analysis as previously described.30
The chips were loaded with 600 ng protein G (P4689, Sigma-
Aldrich) per spot and preincubated in a humidity chamber at room
temperature for 3 hours. After inactivation with Tris-buffer (pH 8),
they were incubated for another 30 minutes followed by washing
another 2 times with phosphate buffered saline (PBS, Sigma-
Aldrich) 1% Triton X-100 (Sigma-Aldrich) and once with PBS
only. Spots were then loaded with 500 ng anti–α 1 defensin anti-
body each (Table 1). Again, the chips were incubated in a
humidity chamber at room temperature for 3 hours. After
another washing with Tris-buffer, the spots were washed 3 times
with a buffer containing 100 mmol/L sodium phosphate
(pH 7.4), 500 mmol/L sodium chloride, and 0.05% Triton X-100.
Tissue protein lysates (120 μL) were applied to the spots using a
ProteinChip cassette-compatible bioprocessor (Bio-Rad, Hercules,
Calif ), and the chips were incubated in a humidity chamber at
4°C overnight. Subsequently, the chips were washed 3 times
with a sodium phosphate/sodium chloride/Triton X-100 buffer
and 2 times with water before 1 μL of ProteinChip sinapinic acid
energy-absorbing molecules (Bio-Rad) was added to each spot.
The spots were air-dried, and the last step was repeated. The ion
mass of the proteins was analyzed on arrays using the ProteinChip
Reader. Mass spectra of the analyzed probes were normalized with
total ion current and signal cluster analysis of signals exhibiting
a signal-to-noise ratio of at least 2.
Pancreatic Tissue Genome Analysis
Human pancreatic tissue samples were collected during sur-
gery and were snap frozen in liquid nitrogen directly after resec-
tion and subsequently stored at −80°C until being used in the
analysis as described above. The frozen tissue samples were cut
into slices of 10 to 20 μm thickness with a cryotome, submerged
in liquid nitrogen, and gently ground by 3 turns of a polypropylene
micropestle (Eppendorf, Hamburg, Germany) that fits into 2-mL
Eppendorf tubes.
Total RNA from individual tissue samples (n = 195 of
PDAC, n = 59 of CP, n = 41 of healthy pancreatic tissues) was iso-
lated with the AllPrep Isolation kit (Qiagen, Hilden, Germany),
following the protocol suggested by themanufacturer, and analyzed
on Sentrix Human-6v3 Whole Genome Expression BeadChips
(Sentrix Human WG-6; Illumina, San Diego, Calif ). To synthesize
the first and second strand cDNA and amplify biotinylated cRNA
from the total RNA, an Illumina Totalprep RNA Amplification
Kit (Illumina) was used. The hybridization to the BeadChip was
performed. All this was done according to the manufacturer's in-
structions. A maximum of 10 μL cRNAwas mixed with a 20 μL© 2018 Wolters Kluwer Health, Inc. All rights reserved.
ealth, Inc. All rights reserved.
TABLE 1. Primary Antibodies Used in Immunohistochemical Stainings and SELDI-TOF-MS
Antigen Antibody Type/Host Manufacturer Dilution Used
Immunohistochemistry
Human defensin β 1 HBD12-A Polyclonal/rabbit Alpha Diagnostics, San Antonio, Tex 1:50
Human defensin β 2 14338-v Antiserum/rabbit Peptide Institute, Osaka, Japan 1:200
Human defensin β 3 LS-B86 Polyclonal/rabbit Lifespan Biosciences, Seattle, Wash 1:100
Human defensin α 1 BS3505 Polyclonal/rabbit Bioworld Technology, Minn 1:100
Human defensin α 3 NBP1-19734 Polyclonal/rabbit Novus Biologicals, Littleton, Colo 1:100
Human defensin α 5 NB110-60002 Monoclonal/mouse Novus Biologicals, Littleton, Colo 1:50
Human defensin α 6 HPA019462 Polyclonal/rabbit Atlas Antibodies, Stockholm, Sweden 1:1000
Human CD15 M3631 Monoclonal/mouse DAKO, Glostrup, Denmark 1:50
SELDI-TOF-MS
Human defensin α 1 ab90486 Monoclonal/mouse Abcam, Cambridge, United Kingdom —
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ple was dispensed onto the large sample port of each array and in-
cubated for 18 hours at 58°C. After hybridization, the samples
were washed according to the protocol and scanned with a
BeadArray Reader (Illumina).
In Vitro Analysis of Defensin Expression in
Pancreatic Cell Cultures
Three representative human pancreatic cancer cell lines were
chosen for experiments (for cell growth curves see Supplemental
Digital Content, http://links.lww.com/MPA/A652): the slow-growing
cell line Colo 357 originated from a lymphatic metastasis of an ade-
nocarcinoma of the pancreas (provided by R.Metzgar, Duke Univer-
sity, Durham, NC, Px 9-28); the PANC-1 cell line originated from
cells of ductal pancreatic adenocarcinoma growing at intermediate
speed (ATCC, Rockville, Md, Px 16-27); and the fast-growing cell
line T3M4 also originated from a lymphaticmetastasis of an exocrine
tumor of the pancreas (provided by R. Metzgar, Duke University,
Durham, NC, Px 14-31).
Cell lines were grown in complete medium (RPMI 1640,
Gibco Invitrogen, Carlsbad, Calif ) containing 10% fetal bovine
serum (Pan Biotech, Aidenbach, Germany) and 1% penicillin-
streptomycin (Gibco Invitrogen), and incubated at 37°C in a
3.5% CO2 humidified atmosphere. For passaging, the cells were
washed with 10 mL Dulbecco's PBS (Promocell, Heidelberg,
Germany) before detachment by Trypsin 0.25% ethylenedi-
aminetetraacetic acid (Gibco Invitrogen) was stopped by adding
complete Roswell Park Memorial Institute medium (RPMI
medium, Sigma-Aldrich).
To compare human neutrophil peptide 1 (HNP-1) expression
by malignant and nonmalignant human pancreas cells, probes
from immortalized human normal human pancreatic duct epithe-
lial cell line cultures (HPDE; provided by M.S. Tsao, University
of Toronto, Toronto, Canada) were generated. HPDE were grown
in Keratinocyte-SFM with L-glutamine, without calcium chloride
containing bovine pituitary extract (25 μg/mL, Gibco Invitrogen) and
recombinant epithelial grwoth factor (0.2 ng/mL, Gibco Invitrogen).
All cells were seeded in 6-well plates. After 24 hours of adher-
ence, the medium was changed into a serum-free special medium
for immunological studies (AIM V medium, Gibco Invitrogen) to
prevent interference of serum proteins with cytokines.
After incubation of cells for 0 hours, 24 hours, and 48 hours,
the mediumwas aspirated and dead cells were discarded after cen-
trifugation for 6 minutes at 1200 rpm. Supernatant and cell pellets
were separated. Cell pellets were incubated in RIPA buffer on ice
for 10 minutes and mechanically resuspended before breakdown© 2018 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2018 Wolters Kluwer to lysate by repeated aspiration through a cannula. Lysate was cen-
trifuged for 15minutes at 13,000 rpm, and cell debriswas discarded.
All probes (n = 6–9 per group) were immediately frozen at −80°C
and stored until analysis.
In Vitro Stimulation of Cancer Cells With
Proinflammatory Cytokines
The effects of proinflammatory cytokines on tumor cell-
specific expression of HNP-1 were studied by adding recombinant
bioactive human tumor necrosis factor α (TNF-α), recombinant
bioactive human interleukin (IL) 1β, and recombinant bioactive hu-
man interferon (IFN) γ (all R&D Systems, Minneapolis, Minn) to
the cell cultures. Cytokines were all added at a concentration of
100 ng/mL. The concentration of the cytokines was set at this level
after a pilot series of cell growth assays. Increasing concentration
levels of cytokines up to 100 ng/mL of the cytokines were shown
to have no influence on the growth rate and survival of the cells
(data not shown). Probes of supernatants and lysates (n = 6–9 per
group) were collected at 0 hours, 24 hours, and 48 hours after incu-
bation for analysis by SELDI-TOF-MS, as described above.
Expression Analysis in Cell Culture
SELDI-TOF-MS analysis of cell lysates and supernatants of
human pancreatic cancer cell line cultures and HPDE cultures was
performed in a way analogous to the tissue analysis described pre-
viously with the application of 200 μL of cell-culture supernatants
and 75 μL of cell lysates per spot.
Data Analysis
Statistical analyses of defensin protein expression were per-
formed using GraphPad Prism (version 3.0; GraphPad Software,
San Diego, Calif ). Student’s t-test (unpaired, two-tailed) was ap-
plied to compute P values. For statistical analyses of genomic ex-
pression, R (R Foundation, Vienna, Austria, http://www.R-project.
org) was used. Significant differentially expressed genes were de-
tected using the limma package of R/Bioconductor by pairwise
comparisons of the sample groups.31 The resulting P values were
adjusted for multiple testing using Benjamini-Hochberg's false
discovery rate method.32
RESULTS
Human neutrophil peptide 1was specifically detected in tissue
samples by the immunohistochemical staining. Protein expression
was most pronounced in the apical cytoplasm of malignant ductal
pancreatic epithelial cells (Fig. 1) but also to a lesser degree and dif-
fusely distributed in CP. In healthy pancreas, HNP-1 was detectedwww.pancreasjournal.com 563
Health, Inc. All rights reserved.
FIGURE 1. Immunohistochemical detection of HNP-1 in human pancreatic tissue. Immunohistochemical staining of HNP-1 shows scarcely
detection in healthy pancreatic tissue (A), light diffusely distributed expression in CP (B) and strong expression in PDAC with emphasis on
apical cytoplasm of malignant ductal epithelial cells (C). Lower pictures of anti-CD15 staining (D–F) show accumulation of inflammatory cells
in CP, not in healthy pancreas and PDAC. Images are representative of 20 independent stainings per group (original magnifications, 20).
Editor’s note: A color image accompanies the online version of this article.
FIGURE 2. Human neutrophil peptide 1 expression in pancreatic
tissue. In mass spectrometric analysis, elevated expression levels
of HNP-1 were found in CP compared with healthy pancreas
(statistically not significant, P = 0.235). In addition, expression levels
were significantly increased in PDAC comparedwith healthy pancreas
and compared with CP (n = 7 per group). Tot. indicates total.
Pausch et al Pancreas • Volume 47, Number 5, May/June 2018only scarcely. Likewise, defensinsα 3 (HNP-3) andβ 5 human beta
defensin (HBD-5) were stained in pancreatic duct epithelia but
without obvious differences between healthy pancreas, CP, and
PDAC (not shown). Defensin β 1 (HBD-1) was stained in
healthy pancreas, but it could hardly be found in CP and PDAC
(not shown). Immunohistochemical staining against human CD15
showed the accumulation of inflammatory cells in the tissue of
CP, but not in healthy pancreas and PDAC (Fig. 1).
In the mass spectrometric analysis, slightly elevated expres-
sion levels of HNP-1 were found in CP compared with healthy pan-
creas (P = 0.235). Expression levels were significantly increased in
PDAC compared with the healthy pancreas (P = 0.003) and to CP
(P = 0.024) (Fig. 2).
A typical finding of SELDI-TOF-MS analysis is demon-
strated in Figure 3. The peak of the ionized HNP-1 protein is ob-
served at 3.45 kDa.
On a nuclear level, HNP-1 was represented by 2 different
probe sequences (ILMN_1679357 and ILMN_2193213) on
Illumina Whole Genome Expression Bead Chips with average
q-normalized log expression level of 6.17 and 5.97. No significant
differences were found between healthy pancreas, CP, and PDAC
in the expression of HNP-1 on RNA level (healthy pancreas vs CP
P = 0.586 and 0.914; healthy pancreas vs PDAC P = 0.226 and
0.977; CP vs PDAC P = 0.701 and 0.751).
In vitro experiments verified the expression of HNP-1 in all
of the 3 pancreatic cancer cell lines with higher expression levels
in cell lysates compared with supernatants (mean, 71 ng/mL total
protein concentration in lysates and 17 ng/mL in supernatants).
Smaller amounts of HNP-1 were found in nonmalignant pancre-
atic ductal epithelial cells (mean, 34 ng/mg total protein concen-
tration in lysates and 5 ng/mg in supernatants). However, HNP-1
expression was significantly higher in supernatants (P = 0.0004)
and also in lysates (P = 0.04) of pancreatic cancer cell lines
(Fig. 4) compared with nonmalignant pancreatic ductal epithelial
cells at 0 to 48 hours of incubation.
Cancer cells that had been stimulated in vitrowith proinflam-
matory cytokines demonstrated significantly increased expression
levels of HNP-1 in cell culture supernatants. When Colo 357 cells
were stimulated with IL-1β, significantly higher levels of HNP-1
were measured in the supernatants compared with unstimulated564 www.pancreasjournal.com
Copyright © 2018 Wolters Kluwer Hcells at 48 hours (P = 0.008) (Fig. 5A). Likewise, after stimulation
of PANC-1 and T3M4 cells with IL-1β (Figs. 5B, D) or IFN-γ
(Figs. 5C, E), HNP-1 protein levels in the supernatants were
significantly higher than in the unstimulated situation at 48 hours
(PANC-1, P = 0.0013 and P = 0.007; T3M4, P = 0.003 and
P = 0.027, respectively).
Cell lysates were found to contain only temporarily decreased
levels of HNP-1 after inflammatory stimulation. At 48 hours, a sig-
nificant decrease in the amount of HNP-1 in stimulated cell lysates
was only seen if all cancer cell lines were summarized before calcu-
lation (P < 0.001, data not shown). If cell lines were analyzed sep-
arately, significant decreases were only found in lysates of T3M4
cells at 24 hours after incubationwith TNF-α, and IL-1β at 48 hours
after incubationwith TNF-α (P = 0.026,P = 0.0002, andP = 0.009,
data not shown).
When nonmalignant HPDE cells had been stimulated with
TNF-α, IL-1β, or IFN-γ, no increases of HNP-1 were seen at
all. A significant decrease of HNP-1 expressionwas found in super-
natants and in lysates of HPDE cells at 48 hours after stimulation© 2018 Wolters Kluwer Health, Inc. All rights reserved.
ealth, Inc. All rights reserved.
FIGURE 3. Example peak of HNP-1 in SELDI-TOF-MS analysis (3.45 kDa).
Pancreas • Volume 47, Number 5, May/June 2018 Defensin α 1 in Pancreatic Cancerwith TNF- α, IL-1β, and IFN-γ (for all supernatants P = 0.004; for
all lysates P = 0.006, data not shown).DISCUSSION
To the best of our knowledge, the present study shows for the
first time that an antimicrobial peptide, in particular HNP-1, is
strongly expressed in malignant human pancreatic tissue in vivo
and in malignant human pancreatic epithelial cells in vitro. Proin-
flammatory stimuli induced the secretion of HNP-1 by pancreatic
tumor cells and may therefore indicate a possible role of defensins
in inflammation-related pancreatic carcinogenesis.
Defensins are physiologically expressed by human epithelia
and immune cells to protect our body against various pathogens.
Being part of both the innate and adaptive immune systems, they
link the first to the second line of defense in the battles on our
body's surfaces.15 Being important modulators of several epithe-
lial intracellular mechanisms, they act asmediators of intercellular
interactions between multiple cells in the epithelial surroundings.
Thereby, defensins have an effect on physiological regenerative
and proliferative processes18 and they participate in the regulation
of acute and chronic inflammatory processes.15 Unsurprisingly,
their role has been studied in conditions of uncontrolled prolifera-
tion, and they have been described as having multiple influences
on cancer cells; for example, HNP-1 to -3 have been demonstrated
to promote proliferation and invasiveness of renal, bladder, oral squa-
mous cell carcinoma, and invasive head and neck carcinoma, and
they have been found to be upregulated in these cancers.20,23,33,34
Defensins also seem to play an important role in the carcinogenesis
of gastrointestinal tumors. Human neutrophil peptide 1 expression in
the tissue of intestinal-type gastric cancer has been correlated with
reduced survival,24 and the overexpression of HNP-1 to -3 has been
shown in tumor cells, serum, and stool of patients with colorectal
cancer.25 Alterations of defensin expression during malignant trans-
formation caused by permanent proinflammatory stimulation have
been described, for example, in colorectal cancer consecutive to in-
flammatory bowel disease.35 Acute and chronic pancreatitis on the
other hand may occur as an extra-intestinal comorbidity of inflam-
matory bowel disease.36 Various defensins have been postulated toFIGURE 4. In vitro analysis of HNP-1 expression in pancreatic adenoma
lines was verified in vitro using mass spectrometry. Human neutrophil pe
(A) and also in supernatants (P ≤ 0.0004) (B) of all 3 pancreatic cancer c
pancreatic ductal cells (HPDE) (0–48 hours) (n = 18–26 per group).
© 2018 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2018 Wolters Kluwer play a role in pancreatic diseases. Human beta defensin 1 (HBD-1)
and HNP-3 secreted by acinar cells may prevent the invasion of bac-
teria from the proximal small intestine.26,27 Polymorphisms of
HBD-1 and HBD-2 have been associated with severe acute pan-
creatitis,28 and the detection of human defensin α 5 (HAD-5) in
pancreatic metaplasia has been seen as an indicator of the
adenoma-carcinoma sequence.29
In the present study, HNP-1 was found to be expressed at
a significantly higher level in malignant human pancreatic tissue
than in healthy pancreas or in CP. These findings support the
hypothesis that defensins, in particular HNP-1, may represent
an important link between chronic inflammation and malignant
transformation in the pancreas. Because physiologically HNP-1
is mainly expressed by granulocytes, it can be hypothesized that
the concentrations of protein measured in the present study
could be biased by the presence of inflammatory cells in the
tumor microenvironment. Three findings contradict this hypothe-
sis: first, immunohistochemical screening for defensins showed
specific HNP-1 staining of pancreatic ductal epithelial cells; sec-
ond, staining of the neutrophil marker CD15 showed the specific
accumulation of inflammatory cells in our CP tissue samples and
not in our PDAC tissue samples, contrary to the HNP-1 staining;
and third, quantitative analysis of HNP-1 expression was per-
formed subsequent to the careful selection of representative
samples by a specialized pathologist and quantification showed
significantly higher amounts of HNP-1 expressed in PDAC tis-
sue compared with CP tissue. Therefore, the fact that HNP-1
was highly expressed in malignant pancreatic tissue and by
proinflammatory-stimulated pancreatic cancer cells but not by in-
flammatory cells as usual emphasizes the importance of the role
HNP-1 might be playing in the inflammatory-triggered develop-
ment of pancreatic cancer.
Like in human tissue, HNP-1 was strongly expressed by var-
ious pancreatic cancer cell lines, but barely by benign pancreatic
ductal cells. This HNP-1 overexpression in malignant cells could
additionally be triggered by proinflammatory cytokines. Cyto-
kines used for this stimulation are known to be involved in sys-
temic inflammation and in CP.13,37 In addition, they are known
to increase survival of pancreatic cancer cells via the nuclearand carcinoma cells. Expression of HNP-1 by pancreatic cancer cell
ptide 1 expression was significantly higher in lysates (P ≤ 0.04)
ell lines (T3M4, PANC-1, Colo 357) as compared with benign
www.pancreasjournal.com 565
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FIGURE 5. In vitro stimulation of pancreatic cancer cell lines (A–B: Colo 357; C–D: PANC-1; E–F: T3M4) with proinflammatory cytokines.
Stimulation of all cancer cell lines with IL-1β (A, C, E) and IFN-γ (B, D, F) significantly increased the amount of HNP-1 in the supernatants
(*P < 0.05; **P < 0.01; ***P < 0.001).
Pausch et al Pancreas • Volume 47, Number 5, May/June 2018factor kappa-light-chain-enhancer of activated B-cells and c-Jun
N-terminal kinases pathways.38 As α defensins are alternatively
termed human neutrophil peptides, HNP-1 is highly expressed
by granulocytes and secreted from their azurophil granules on
infectious and proinflammatory stimulation.15 Accordingly,
HAD-5 and HAD-6 are shed by Paneth and intermediate cells in
the small intestine.39 Thus, we assume that pancreatic cancer cells
might secrete HNP-1 by analogous mechanisms. Significant HNP-1
excretion was reflected by a significant increase of HNP-1 con-
centration in supernatants 48 hours after incubation of cancer cells
with proinflammatory cytokines. However, a representative decrease
of HNP-1 in stimulated cell lysates was only seen to be statistically
significant after 48 hours when all 3 cancer cell lines were summa-
rized for calculation. In separate analysis, a significant decrease of
HNP-1 concentration could only be seen in lysates of T3M4. Worth
mentioning in this context is the fact that most characteristically the
proinflammatory stimulated T3M4 cell is the fastest growing of all
3 pancreatic cancer cell lines used in this study.
Our findings do not claim to describe a singular 1-way pathway
from chronic inflammation to cancer via cytokines and defensins. In
fact, they solely demonstrate that certain proinflammatory cytokines,
which are known to be present in tissue of CP,15 can induce HNP-
1-expression by pancreatic cancer cells as one potential link
between CP and PDAC.
To discuss the precise nature of this link, one has to consider
the 2 domains in which defensins act: on the one hand, they are an-
timicrobial peptides bringing death to invading bacteria and viruses;566 www.pancreasjournal.com
Copyright © 2018 Wolters Kluwer Hon the other hand, they are known to be important intercellular medi-
ators, not only linking innate to adaptive immunity but also regulating
multiple regenerative and proliferative processes both physiologically
and pathologically in our body. The involvement of microorganisms
in carcinogenesis in the pancreas has been studied, and viral infec-
tions with mumps and hepatitis B virus as well as bacterial infec-
tion with Helicobacter pylori have been described as risk factors.40
Specific publications about the pancreas are inconsistent, and the
organ itself is not in intense microbiological contact. Therefore,
it remains a daring hypothesis to argue that dysbiosis in the pan-
creas causes inflammatory-triggered malignant transformation
with the contribution of antimicrobial factors. It is noteworthy
that a strong desmoplastic reaction is a characteristic feature of
PDAC, involving multiple cells in the tumor microenvironment
and promoting the progression of the disease.16,17,41 In this con-
text, the role of defensins as an important link between chronic
inflammation and carcinogenesis in the pancreas needs further
evaluation. Pancreatic stellate cells (PSCs) appear to be key
players in the stromal-epithelial interaction in PDAC,17 and their
physiologically quiescent status can be ended pathologically by
growth factors, cytokines, and oxidative stress. Pancreatic stel-
late cells are an obvious area of interest concerning the influence
of defensins in the pancreas, because PSCs are located basolaterally
of pancreatic acinar cells, which again are known to produce
HBD-127; furthermore, the activation of PSCs has been shown
to be caused by alcohol and by bacterial endotoxin lipopolysac-
charide.42 Upcoming studies about defensins as a potential link© 2018 Wolters Kluwer Health, Inc. All rights reserved.
ealth, Inc. All rights reserved.
Pancreas • Volume 47, Number 5, May/June 2018 Defensin α 1 in Pancreatic Cancerbetween CP and PDAC need to focus on the possible influence
of defensins on cell interactions as well as on their possible direct
nuclear effect on cancer cells.
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